GEAN TO 2 — Genetic Analysis As Income Statement
0.000.00%
Last trade - 00:00- NOK23.17m
- NOK19.32m
- NOK11.16m
Annual income statement for Genetic Analysis As, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.12 | 7.29 | 5.78 | 6.8 | 11.2 |
| Cost of Revenue | |||||
| Gross Profit | 2.37 | 5.56 | 4.75 | 5.52 | 7.26 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 24.1 | 14 | 27.7 | 35.7 | 39.3 |
| Operating Profit | -19.9 | -6.75 | -22 | -28.9 | -28.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.5 | -6.94 | -22.1 | -29 | -28.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.5 | -6.94 | -22.1 | -29 | -28.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.5 | -6.94 | -22.1 | -29 | -28.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.5 | -6.94 | -22.1 | -29 | -28.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.327 | -0.101 | -0.201 | -1.16 | -1.13 |